Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Atavistik Bio, Inc
Duke University
AstraZeneca
OHSU Knight Cancer Institute
City of Hope Medical Center
NeoTX Therapeutics Ltd.
Medtronic - MITG
Memorial Sloan Kettering Cancer Center
Vanderbilt-Ingram Cancer Center
University of Alabama at Birmingham
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
Theratechnologies
Memorial Sloan Kettering Cancer Center
Xencor, Inc.
Agenus Inc.
Carisma Therapeutics Inc
University of Toronto
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc